Lea E Widdice1, David I Bernstein2, Eduardo L Franco3, Lili Ding4, Darron R Brown5, Aaron C Ermel6, Lisa Higgins7, Jessica A Kahn8. 1. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Division of Adolescent and Transition Medicine, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH, USA. Electronic address: lea.widdice@cchmc.org. 2. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH, USA. Electronic address: david.bernstein@cchmc.org. 3. Department of Oncology and Department of Epidemiology & Biostatistics, McGill University, Faculty of Medicine, 5100 Maisonneuve Blvd West, Suite 720, Montreal, QC H4A3T2, Canada. Electronic address: eduardo.franco@mcgill.ca. 4. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH, USA. Electronic address: lili.ding@cchmc.org. 5. Department of Medicine and Department of Microbiology and Immunology, Indiana University School of Medicine, 635 Barnhill Dr., Van Nuys Medical Sciences Building, Suite 224, Indianapolis, IN 46202, USA. Electronic address: darbrow@iu.edu. 6. Department of Medicine and Department of Microbiology and Immunology, Indiana University School of Medicine, 635 Barnhill Dr., Van Nuys Medical Sciences Building, Suite 224, Indianapolis, IN 46202, USA. Electronic address: aermel@iu.edu. 7. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Division of Adolescent and Transition Medicine, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH, USA. Electronic address: lisa.higgins@cchmc.org. 8. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Division of Adolescent and Transition Medicine, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH, USA. Electronic address: Jessica.kahn@cchmc.org.
Abstract
PURPOSE: The aim of this study was to determine changes in human papillomavirus (HPV) prevalence among young men from a Midwest metropolitan area over the six years after vaccine introduction, including HPV prevalence in men overall, in vaccinated men to examine vaccine impact and in unvaccinated men to examine herd protection. An exploratory aim was to examine associations between number of vaccine doses and HPV prevalence. METHODS: Men aged 14-26 years reporting male-female and/or male-male sexual contact were recruited from a primary care clinic, sexually transmitted disease clinic, and community setting during two waves of data collection: 2013-2014 (N = 400) and 2016-2017 (N = 347). Participants completed a questionnaire and were tested for penile, scrotal and anal HPV. Changes in prevalence of any (≥1 type) and vaccine-type HPV (HPV6, 11, 16, and/or 18) were examined using propensity score weighted logistic regression. Associations between number of doses and HPV infection were determined using chi-square tests and logistic regression. RESULTS: The proportion of men with a history of ≥1 HPV vaccine doses increased from 23% to 44% (p < 0.001) from waves 1 to 2. After propensity score weighting, infection with ≥1 vaccine-type HPV significantly decreased among all men (29% to 20%; 31% decrease; odds ratio [OR] = 0.62, 95% confidence interval [CI] = 0.44-0.88) and unvaccinated men (32% to 21%; 36% decrease; OR = 0.56, 95%CI = 0.34-0.86); there was a non-significant decrease (21%) among vaccinated men. Associations between number of doses and HPV prevalence were not statistically significant. CONCLUSIONS: Prevalence of vaccine-type HPV decreased among all, vaccinated, and unvaccinated men six years after HPV vaccine recommendation, supporting vaccine impact and herd protection. Decreases in vaccine-type HPV in all men appear to be due to decreases in unvaccinated men, suggesting that the full impact of vaccination has yet to be realized. Continued monitoring and efforts to vaccinate men prior to sexual initiation are warranted.
PURPOSE: The aim of this study was to determine changes in human papillomavirus (HPV) prevalence among young men from a Midwest metropolitan area over the six years after vaccine introduction, including HPV prevalence in men overall, in vaccinated men to examine vaccine impact and in unvaccinated men to examine herd protection. An exploratory aim was to examine associations between number of vaccine doses and HPV prevalence. METHODS:Men aged 14-26 years reporting male-female and/or male-male sexual contact were recruited from a primary care clinic, sexually transmitted disease clinic, and community setting during two waves of data collection: 2013-2014 (N = 400) and 2016-2017 (N = 347). Participants completed a questionnaire and were tested for penile, scrotal and anal HPV. Changes in prevalence of any (≥1 type) and vaccine-type HPV (HPV6, 11, 16, and/or 18) were examined using propensity score weighted logistic regression. Associations between number of doses and HPV infection were determined using chi-square tests and logistic regression. RESULTS: The proportion of men with a history of ≥1 HPV vaccine doses increased from 23% to 44% (p < 0.001) from waves 1 to 2. After propensity score weighting, infection with ≥1 vaccine-type HPV significantly decreased among all men (29% to 20%; 31% decrease; odds ratio [OR] = 0.62, 95% confidence interval [CI] = 0.44-0.88) and unvaccinated men (32% to 21%; 36% decrease; OR = 0.56, 95%CI = 0.34-0.86); there was a non-significant decrease (21%) among vaccinated men. Associations between number of doses and HPV prevalence were not statistically significant. CONCLUSIONS: Prevalence of vaccine-type HPV decreased among all, vaccinated, and unvaccinated men six years after HPV vaccine recommendation, supporting vaccine impact and herd protection. Decreases in vaccine-type HPV in all men appear to be due to decreases in unvaccinated men, suggesting that the full impact of vaccination has yet to be realized. Continued monitoring and efforts to vaccinatemen prior to sexual initiation are warranted.
Authors: Zhiyue Liu; Alan G Nyitray; Lu-Yu Hwang; Michael D Swartz; Martha Abrahamsen; Eduardo Lazcano-Ponce; Luisa L Villa; Anna R Giuliano Journal: J Infect Dis Date: 2018-02-14 Impact factor: 5.226
Authors: Jessica A Kahn; Lea E Widdice; Lili Ding; Bin Huang; Darron R Brown; Eduardo L Franco; David I Bernstein Journal: Clin Infect Dis Date: 2016-09-20 Impact factor: 9.079
Authors: Jessica A Kahn; Susan L Rosenthal; Yan Jin; Bin Huang; Azadeh Namakydoust; Gregory D Zimet Journal: Obstet Gynecol Date: 2008-05 Impact factor: 7.661
Authors: Lea E Widdice; Darron R Brown; David I Bernstein; Lili Ding; Deesha Patel; Marcia Shew; J Dennis Fortenberry; Jessica A Kahn Journal: Arch Pediatr Adolesc Med Date: 2012-08
Authors: Eric P F Chow; Dorothy A Machalek; Sepehr N Tabrizi; Jennifer A Danielewski; Glenda Fehler; Catriona S Bradshaw; Suzanne M Garland; Marcus Y Chen; Christopher K Fairley Journal: Lancet Infect Dis Date: 2016-06-06 Impact factor: 25.071
Authors: Ross L Cameron; Kimberley Kavanagh; Jiafeng Pan; John Love; Kate Cuschieri; Chris Robertson; Syed Ahmed; Timothy Palmer; Kevin G J Pollock Journal: Emerg Infect Dis Date: 2016-01 Impact factor: 6.883
Authors: Kimberley Kavanagh; Kevin G Pollock; Kate Cuschieri; Tim Palmer; Ross L Cameron; Cameron Watt; Ramya Bhatia; Catherine Moore; Heather Cubie; Margaret Cruickshank; Chris Robertson Journal: Lancet Infect Dis Date: 2017-09-28 Impact factor: 25.071